- Home
- CURI vs SLN Comparison
CURI vs SLN Comparison
Compare CURI & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURI
- SLN
- Stock Information
- Founded
- CURI 2008
- SLN 1994
- Country
- CURI United States
- SLN United Kingdom
- Employees
- CURI N/A
- SLN N/A
- Industry
- CURI Movies/Entertainment
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- CURI Consumer Discretionary
- SLN Health Care
- Exchange
- CURI Nasdaq
- SLN Nasdaq
- Market Cap
- CURI 264.7M
- SLN 268.8M
- IPO Year
- CURI N/A
- SLN N/A
- Fundamental
- Price
- CURI $4.85
- SLN $4.51
- Analyst Decision
- CURI Strong Buy
- SLN Buy
- Analyst Count
- CURI 2
- SLN 5
- Target Price
- CURI $5.75
- SLN $32.60
- AVG Volume (30 Days)
- CURI 626.3K
- SLN 53.7K
- Earning Date
- CURI 11-05-2025
- SLN 11-13-2025
- Dividend Yield
- CURI 6.60%
- SLN N/A
- EPS Growth
- CURI N/A
- SLN N/A
- EPS
- CURI N/A
- SLN N/A
- Revenue
- CURI $60,840,000.00
- SLN $27,169,000.00
- Revenue This Year
- CURI $34.06
- SLN N/A
- Revenue Next Year
- CURI $11.70
- SLN N/A
- P/E Ratio
- CURI N/A
- SLN N/A
- Revenue Growth
- CURI 11.02
- SLN 22.28
- 52 Week Low
- CURI $1.47
- SLN $1.97
- 52 Week High
- CURI $7.15
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- CURI 61.55
- SLN 36.54
- Support Level
- CURI $4.31
- SLN $4.77
- Resistance Level
- CURI $4.71
- SLN $5.80
- Average True Range (ATR)
- CURI 0.22
- SLN 0.39
- MACD
- CURI 0.04
- SLN -0.03
- Stochastic Oscillator
- CURI 98.41
- SLN 0.77
About CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.